被两家央企先后涉猎,并险些“捕获”的上药,在迷茫三年后,将如何在上海本地国资的主导下重振这是一场横跨沪港两地4家上市公司的重组。重组后,两家医药上市公司将被注销,一家上市公司医药资产将被清空——吸纳了三家上市公司医药资产,拥有研发、制造、分销、零售完备产业链的“新上药”横空出世。 The two central enterprises have been involved in, and almost “capture ” on the drug, confused three years later, how to revitalize under the leadership of local capital in Shanghai This is a cross-Shanghai and Hong Kong listed companies four Reorganization. After the reorganization, the two pharmaceutical listed companies will be canceled and the pharmaceutical assets of a listed company will be emptied - the pharmaceutical assets of the three listed companies have been absorbed and the “new medicine” horizontal research and development, manufacturing, distribution and retail chain Empty was born.